Sigachi Industries, manufacturer of pharmaceutical excipients and specialty ingredients, has received environmental clearance (EC) from the State Environment Impact Assessment Authority (SEIAA), Gujarat, for its upcoming greenfield manufacturing facility at Dahej SEZ, Bharuch. This marks a significant milestone in one of the company’s largest capacity expansion initiatives to date.
Strategic Location to Fuel Export-Led Growth
The new facility is strategically located within the Dahej Special Economic Zone (SEZ). This move is aimed at enhancing export potential, increasing operational efficiency, and ensuring adherence to global regulatory standards. The SEZ setting offers Sigachi key advantages, including tax incentives, ease of doing business, and proximity to key ports and global supply chain networks.
Expanding Product Portfolio and Market Reach
Sigachi plans to equip the Dahej facility with an installed capacity of 3,120 metric tons per month, ensuring significant production capability. The company will manufacture a diverse range of cellulose- and starch-based excipients, along with other high-value functional ingredients. Sigachi targets these products at the pharmaceutical, nutraceutical, and food-grade industries to tap into high-growth, high-margin global segments.
Strengthening Global Competitiveness
The greenfield project is a major step forward in Sigachi’s global expansion strategy. It strengthens the company’s manufacturing base while increasing regulatory readiness for both regulated and semi-regulated markets. The facility’s capacity and compliance capabilities will allow Sigachi to respond swiftly to growing global demand.
Supporting ‘Make in India’ and Export Ambitions
The Dahej project reinforces Sigachi’s alignment with India’s “Make in India” initiative and the country’s broader push toward export-oriented industrial growth. As reported by projectstoday.com, Sigachi is investing in advanced manufacturing infrastructure and expanding its international footprint. Through these efforts, the company is positioning itself at the forefront of India’s pharmaceutical manufacturing evolution.
